bioMerieux (BIM) AI Stock Analysis

• Market Cap: €10.65B
• Dividend Yield: 0.82%
• Average Volume (3M): 107.98K
• Price to Earnings (P/E): 32.7
• Beta (1Y): 0.53
• Revenue Growth: 8.28%
• EPS Growth: -8.08%
• Country: FR
• Employees: 14,147
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 2.00
• Shares Outstanding: 118,361,220
• 10 Day Avg. Volume: 122,242
• 30 Day Avg. Volume: 107,982
• PEG Ratio: -4.00
• Price to Book (P/B): 3.17
• Price to Sales (P/S): 3.20
• P/FCF Ratio: 28.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €112.40
• Price Target Upside: 24.61% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 5
• EPS Forecast (FY): 4.81
• Revenue Forecast (FY): €4.25B

• Rating: 68 Neutral
• Price Target: €98.00 ▲(8.65% Upside)
• Action: Reiterated Date: 03/01/26
• Date: Action: Reiterated 03/01/26

The score is primarily supported by a strong, low-leverage balance sheet and generally solid profitability, tempered by softer recent growth and mixed cash conversion. Technicals are a secondary drag with the stock still below key longer-term moving averages and a negative MACD, while valuation looks demanding given the ~29.7 P/E and modest ~0.9% yield.

Positive Factors

Recurring consumables model

bioMérieux's instrument-plus-consumables model creates durable, repeatable revenue as installed analyzers drive continuous reagent and kit demand. This annuity-like stream supports predictable topline annuities, margin visibility, and long-term customer stickiness from replacement cycles and service contracts.

Negative Factors

2025 revenue decline

A year-over-year revenue decline signals weakening demand or tougher procurement/tender dynamics. For a consumables-driven business, sustained revenue softness can slow installed-base growth and reduce future annuity revenue, pressuring long-term organic expansion potential.

bioMerieux Business Overview & Revenue Model

Company Description

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagno...

Read more

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagno...

How the Company Makes Money

bioMérieux makes money primarily by selling diagnostic instruments and, more importantly, recurring consumables used on those instruments. Key revenue streams include: (1) Consumables and reagents (recurring): test kits, cartridges, culture media,...

Read more

bioMérieux makes money primarily by selling diagnostic instruments and, more importantly, recurring consumables used on those instruments. Key revenue streams include: (1) Consumables and reagents (recurring): test kits, cartridges, culture media,...

bioMerieux Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.07B	3.98B	3.67B	3.59B	3.38B
Gross Profit	2.14B	2.22B	2.06B	1.96B	1.97B
EBITDA	999.60M	897.50M	701.30M	811.90M	977.80M
Net Income	397.50M	432.20M	357.60M	452.40M	601.10M
Balance Sheet
Total Assets	5.57B	5.77B	5.26B	5.19B	4.61B
Cash, Cash Equivalents and Short-Term Investments	569.80M	449.80M	352.40M	552.60M	803.50M
Total Debt	461.40M	490.70M	518.80M	505.40M	462.50M
Total Liabilities	1.47B	1.56B	1.51B	1.54B	1.44B
Stockholders Equity	4.10B	4.20B	3.75B	3.60B	3.11B
Cash Flow
Free Cash Flow	453.00M	321.50M	107.10M	188.40M	534.60M
Operating Cash Flow	788.30M	667.30M	445.40M	475.10M	824.70M
Investing Cash Flow	-461.70M	-359.80M	-488.80M	-528.10M	-307.30M
Financing Cash Flow	-155.40M	-212.60M	-122.30M	-244.20M	-140.60M

bioMerieux Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 90.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BIM, the sentiment is Negative. The current price of 90.2 is below the 20-day moving average (MA) of 91.86, below the 50-day MA of 94.12, and below the 200-day MA of 108.90, indicating a bearish trend. The MACD of -1.20 indicates Negative momentum. The RSI at 41.57 is Neutral, neither overbought nor oversold. The STOCH value of 31.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:BIM.

bioMerieux Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIM	68 Neutral	€10.65B	32.73	9.69%	0.82%	8.28%	-8.08%
VIRP	68 Neutral	€3.02B	10.97	12.62%	0.41%	6.97%	-5.59%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ERF	54 Neutral	€11.29B	23.65	11.27%	0.97%	6.25%	18.93%
DIM	52 Neutral	€16.58B	76.93	6.65%	0.31%	7.72%	53.84%